시장보고서

상품코드

1800932

심방세동 치료 시장 보고서 : 질환 유형별, 치료 유형별, 최종사용자별, 지역별(2025-2033년)

Atrial Fibrillation Treatment Market Report by Disorder Type, Treatment Type, End-User, and Region 2025-2033

발행일: 2025년 08월 | 리서치사:

IMARC | 페이지 정보: 영문 117 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 심방세동 치료 시장 규모는 2024년 86억 달러에 달했습니다. IMARC Group은 2033년까지 209억 달러에 달하고, 2025-2033년 연평균 성장률(CAGR)은 9.83%를 보일 것으로 예측했습니다.

심방세동(AFib)은 불규칙하고 빠른 심장 박동으로 뇌졸중, 심부전 및 기타 심장 관련 합병증의 위험을 증가시키는 심장 질환입니다. 이 상태에서는 심방상실이 불규칙하게 박동하고 심실하실과 연동하지 않아 심계항진, 호흡곤란, 피로감을 유발합니다. 또한 혈전 발생으로 이어져 다른 장기로의 혈류를 방해할 수도 있습니다. 심방세동의 주요 유형에는 발작성 심방세동, 지속성 심방세동, 장기 지속성 심방세동, 지속성 심방세동이 있으며, 심장의 전기 자극을 조절하는 약물 및 기타 개입을 통해 치료할 수 있습니다.

심혈관 질환(CVDs)의 유병률 증가는 시장 성장을 가속하는 중요한 요인 중 하나입니다. 이러한 질환은 노인 인구와 당뇨병, 고혈압, 심혈관 질환(CVDs)과 같은 다른 질환을 앓고 있는 사람들 사이에서 매우 흔하게 나타납니다. 이는 전 세계적으로 꾸준히 증가하고 있는 노인 인구와 함께 시장 성장을 견인하고 있습니다. 또한, 최소침습(MI) 수술에 대한 선호도가 높아지면서 소형화 수술 장비, 임플란트 수술, 원격 간호에 대한 수요에도 긍정적인 영향을 미치고 있습니다. 또한, 손상된 심장 조직을 제거하기 위한 카테터 절제 장치와 혁신적인 매핑 및 기록 시스템 개발 등 다양한 기술 발전도 성장을 가속하는 요인으로 작용하고 있습니다. 기타 요인으로는 의료 인프라의 개선과 의료 과학 분야의 광범위한 조사 개발(R&D) 활동이 시장을 더욱 견인할 것으로 예측됩니다.

본 보고서에서 다룬 주요 질문

세계 심방세동 치료제 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 성장할 것인가?
코로나19가 전 세계 심방세동 치료 시장에 미치는 영향은?
주요 지역 시장은?
질병 유형별 시장 분석은?
치료 유형별 시장 분석은?
최종사용자별 시장 분석은?
산업 가치사슬의 다양한 단계는?
업계의 주요 촉진요인과 과제는?
세계 심방세동 치료 시장의 구조와 주요 기업은?
업계 내 경쟁은 어느 정도인가?

의료 시술
- 외과 수술
  - Maze Surgery
  - 카테터 절제
- 비외과용 기기
  - 전기적 심전환
  - 진단용 카테터
  - 매핑 및 기록 시스템
  - 심장 모니터
  - 액세스 디바이스
  - 좌심방 부속기 및 폐쇄 장치
  - 심내 초음파 검사(ICE) 시스템
의약품
- 약제 클래스
  - 항응고제
  - 항부정맥제

제8장 시장 분석 : 최종사용자별

병원
심장 검사실
외래수술센터(ASC)
기타

제9장 시장 분석 : 지역별

북미
- 미국
- 캐나다
아시아태평양
- 중국
- 일본
- 인도
- 한국
- 호주
- 인도네시아
- 기타
유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
라틴아메리카
- 브라질
- 멕시코
- 기타
중동 및 아프리카

제10장 SWOT 분석

제11장 밸류체인 분석

제12장 Porter의 Five Forces 분석

제13장 경쟁 구도

시장 구조
주요 기업
주요 기업 개요
- Abbott Laboratories
- Atricure Inc.
- Biotronik
- Boston Scientific Corporation
- Cardiofocus Inc.
- Hansen Medical Inc.(Auris Health)
- Johnson & Johnson
- Siemens Healthineers
- Stereotaxis Inc.

LSH 25.09.05

The global atrial fibrillation treatment market size reached USD 8.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 20.9 Billion by 2033, exhibiting a growth rate (CAGR) of 9.83% during 2025-2033.

Atrial fibrillation (AFib) refers to a cardiac condition with irregular and rapid heart rate that increases the risks of stroke, heart failure and other heart-related complications. In this condition, the upper (atrial) chambers beat irregularly and out of coordination with the lower (ventricle) chambers of the heart, thereby causing heart palpitations, shortness of breath and fatigue. It can also lead to the development of blood clots that may disrupt the blood flow to other organs. The main types of AFib include paroxysmal, persistent, long-term persistent, and permanent AFib that can be treated with medications and other interventions to adjust the heart's electrical impulses.

The rising prevalence of cardiovascular diseases (CVDs) is one of the key factors driving the growth of the market. Such disorders are highly prevalent among the geriatric population and individuals suffering from other ailments, such as diabetes, hypertension and cardiovascular diseases (CVDs). This, along with the steadily increasing geriatric population across the globe, is providing a boost to the market growth. Furthermore, the increasing preference for minimally invasive (MI) surgical procedures is also creating a positive impact on the demand for miniaturized surgical devices, implant surgeries and remote nursing. Additionally, various technological advancements, such as the development of catheter ablation devices to remove damaged heart tissues and innovative mapping and recording systems, is acting as another growth-inducing factor. Other factors, including improvements in the healthcare infrastructure and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.

Key Market Segmentation:

Breakup by Disorder Type:

Paroxysmal Atrial Fibrillation
Persistent Atrial Fibrillation
Permanent Atrial Fibrillation
Others

Breakup by Treatment Type:

Medical Procedures
- Surgical Procedures
Maze Surgery
Catheter Ablation
- Non-Surgical Procedures
Electric Cardioversion
Diagnostic Catheters
Mapping and Recording Systems
Cardiac Monitors
Access Devices
Left Atrial Appendage and Closure Devices
Intracardiac Echocardiography (ICE) Systems
Medication
- Anticoagulants
- Anti-Arrhythmics

Breakup by End-User:

Hospitals
Cardiac Labs
Ambulatory Surgical Centers
Others

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Atricure Inc., Biotronik, Boston Scientific Corporation, Cardiofocus Inc., Hansen Medical Inc. (Auris Health), Johnson & Johnson, Siemens Healthineers, Stereotaxis Inc., etc.

Key Questions Answered in This Report:

How has the global atrial fibrillation treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global atrial fibrillation treatment market?
What are the key regional markets?
What is the breakup of the market based on the disorder type?
What is the breakup of the market based on the treatment type?
What is the breakup of the market based on the end-user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global atrial fibrillation treatment market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Atrial Fibrillation Treatment Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Disorder Type

6.1 Paroxysmal Atrial Fibrillation
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Persistent Atrial Fibrillation
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Permanent Atrial Fibrillation
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Treatment Type

7.1 Medical Procedures
- 7.1.1 Market Trends
- 7.1.2 Surgical Procedures
  - 7.1.2.1 Maze Surgery
  - 7.1.2.2 Catheter Ablation
- 7.1.3 Non-Surgical Devices
  - 7.1.3.1 Electric Cardioversion
  - 7.1.3.2 Diagnostic Catheters
  - 7.1.3.3 Mapping and Recording Systems
  - 7.1.3.4 Cardiac Monitors
  - 7.1.3.5 Access Devices
  - 7.1.3.6 Left Atrial Appendage and Closure Devices
  - 7.1.3.7 Intracardiac Echocardiography (ICE) Systems
- 7.1.4 Market Forecast
7.2 Medications
- 7.2.1 Market Trends
- 7.2.2 Drug Class
  - 7.2.2.1 Anticoagulants
  - 7.2.2.2 Anti-Arrhythmics
- 7.2.3 Market Forecast

8 Market Breakup by End-User

8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Cardiac Labs
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Ambulatory Surgical Centers
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Competitive Landscape

13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
- 13.3.1 Abbott Laboratories
  - 13.3.1.1 Company Overview
  - 13.3.1.2 Product Portfolio
  - 13.3.1.3 Financials
  - 13.3.1.4 SWOT Analysis
- 13.3.2 Atricure Inc.
  - 13.3.2.1 Company Overview
  - 13.3.2.2 Product Portfolio
  - 13.3.2.3 Financials
  - 13.3.2.4 SWOT Analysis
- 13.3.3 Biotronik
  - 13.3.3.1 Company Overview
  - 13.3.3.2 Product Portfolio
- 13.3.4 Boston Scientific Corporation
  - 13.3.4.1 Company Overview
  - 13.3.4.2 Product Portfolio
  - 13.3.4.3 SWOT Analysis
- 13.3.5 Cardiofocus Inc.
  - 13.3.5.1 Company Overview
  - 13.3.5.2 Product Portfolio
- 13.3.6 Hansen Medical Inc. (Auris Health)
  - 13.3.6.1 Company Overview
  - 13.3.6.2 Product Portfolio
- 13.3.7 Johnson & Johnson
  - 13.3.7.1 Company Overview
  - 13.3.7.2 Product Portfolio
  - 13.3.7.3 Financials
  - 13.3.7.4 SWOT Analysis
- 13.3.8 Siemens Healthineers
  - 13.3.8.1 Company Overview
  - 13.3.8.2 Product Portfolio
  - 13.3.8.3 Financials
- 13.3.9 Stereotaxis Inc.
  - 13.3.9.1 Company Overview
  - 13.3.9.2 Product Portfolio
  - 13.3.9.3 Financials
  - 13.3.9.4 SWOT Analysis